Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Joe E. who wrote (4682)	7/7/1998 7:06:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 6136

Yesterday, BARS came out with a weekly update on PI scrips: Key Points: ú New protease inhibitor scrips were up 0.3% over the previous week's level. Agouron's market share of new protease inhibitor prescriptions was 32.0%, down from 32.8% the previous week. ú Total protease inhibitor scrips were up 1.5%, and Agouron's market share was 31.4%, down from 32.0% the week prior. ú Refill protease inhibitor scrips were up 2.1% versus the previous week. Viracept's market share of refills was 31.0% for the week of June 26, down from 31.6% the previous week.